About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RECRUITINGPhase 2

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

Efficacy of Short-course Blinatumomab in Patients With Detectable Measurable Residual Disease With Philadelphia Chromosome-negative B-cell Acute Lymphoblastyc Leukemia

NCT06886074•Hospital Universitario Dr. Jose E. Gonzalez

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Acute Lymphoblastic LeukemiaMeasurable Residual Disease (MRD)

Interventions

Short course of blinatumomab

Locations

1

Mexico

Locations (1)

Hospital Universitario Dr. Jose E. Gonzalez

Monterrey, Nuevo León, Mexico

Key Dates

Start Date

January 2, 2025

Primary Completion Date

January 1, 2027

Completion Date

June 1, 2027

Last Updated

March 20, 2025

Related Studies

RECRUITINGPhase 2

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

NCT05376111

T-cell Acute Lymphoblastic LeukemiaRecruiting

RECRUITINGPhase 1/2

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399

Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia+3 more

RECRUITINGPhase 2

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

NCT05453500

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

RECRUITINGPhase 1

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

NCT07295951

Acute Lymphoblastic LeukemiaAcute Leukemias+1 more

RECRUITINGPhase 1/2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

NCT05442515

B-NHLB-Non Hodgkin Lymphoma+9 more

RECRUITINGPhase 2

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

NCT03970096

Acute LeukemiaAcute Lymphoblastic Leukemia+3 more

View all related studies

Contacts

Andres Gomez-De Leon, Professor of Hematology

CONTACT

+528116089404 drgomezdeleon@gmail.com

Sponsors

Lead Sponsor

Hospital Universitario Dr. Jose E. Gonzalez

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions